Table 2.
Drug groups | Drugs | Purpose of use in COVID‐19 | Hypersensitivity reactions | In vivo tests in IHRs | In vivo tests in NIHRs | In vitro tests for IHRs | In vitro tests for NIHRs | Desensitization |
---|---|---|---|---|---|---|---|---|
Antiviral drugs | Favipiravir | Viral pneumonia | None | |||||
Lopinavir/Ritonavir | AGEP 61 , MPE 60 | |||||||
Darunavir/Ritonavir |
MPE 66 |
DNIHR 66 , 67 | ||||||
Umifenovir (Arbidol) | None | |||||||
Ribavirin |
Urticaria 58 MPE 56 |
DPT 56 | LTT 57 | DNIHR 58 , 59 | ||||
Remdesivir (GS‐5734) | MPE 51 | |||||||
Oseltamivir |
Anaphylaxis 68 |
SPT 68 | LTT 50 | |||||
Immunomodulatory drugs | Azithromycine |
MPE 73 , 74 , ACD 75 , 76 , FDE 77 Anaphylaxis 72 Urticaria 71 Leukocytoclastic vasculitis 82 Hypersensitivity myocarditis 83 |
DPT 87 |
PT 75 DPT 87 |
DIHR 88 |
|||
Hydroxychloroquine / Chloroquine |
Erythema multiforme 96 Bullous erythema 97 Photoallergic dermatitis 101 ACD 102 |
SPT 109 |
DPT 90 |
|||||
Auranofin | None | |||||||
Interferons |
Local reaction 116 |
DPT 125 |
PT 119 |
DIHR 123 |
||||
Nitazoxanide | None | |||||||
Ivermectin | FDE 129 , DRESS 130 , SJS 131 , TEN 132 |
Abbreviations: ACD, Acute contact dermatitis; AGEP, Acute generalized exanthematous pustulosis; BAT, Basophil activation test; DIHR, Desensitization for immediate hypersensitivity reactions; DNIHR, Desensitization for nonimmediate hypersensitivity reactions;DPT, Drug provocation test; DRESS, Drug‐related eosinophilia systemic symptoms; FDE, Fixed drug eruption; IDT, Intradermal test; IHR, Immediate hypersensitivity reaction; LTT, Lymphocyte transformation test; MPE, Maculopapular eruption; NIHR, Nonimmediate hypersensitivity reaction; PT, Patch test; SJS, Stevens Johnson syndrome; SPT, Skin prick test; ST, Skin test; TEN, Toxic epidermal necrolysis.